02-Mar-2021

Non-small Cell Lung Cancer Treatment Market CAGR of 9.3% Drives the Industry Size, Growth Factors, Technology Advancement, Future Trends, Global Market Scope and Top key Players

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Cancer is a chronic disorder, in which cells grow abnormally or a tumor is formed. Lung cancer is one of the severe types of cancer, in which cells of lungs stats to grow in an uncontrolled manner, giving rise of tumor. Furthermore, this tumor spreads into other body parts. Small cell lung cancer and non-small cell lung cancer are the two main types of lung cancer. According to Lung Cancer Alliance (a leading nonprofit organization dedicated to fighting lung cancer), out of overall lung cancer cases, around 80 to 85% cases are of non-small cell lung cancer type and 15-20% cases found are of small cell lung cancer type.

Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/241

The commonly diagnosed types of non-small cell lung cancer (NSCLC) are adenocarcinoma, squamous cell carcinoma, large cell neuroendocrine tumors, and large-cell carcinoma, of those adenocarcinoma and squamous cell carcinoma accounts around 60% of lung cancer. Although there is no exact reason defined by doctors, the primary prediction is air pollution, smoking, mineral and metal dust, and radiation treatment of breast or chest. Moreover, lung cancer symptoms are not significant as they are considered for other type of illness such as collapsed lung or pneumonia. Some common symptoms of lung cancer include wheezing, hoarseness or voice changes, constant coughing, chest pain, harsh/raspy sound during breathing, shortness of breath, and other lung problems such as pneumonia or bronchitis. Moreover, after the tumor is spread, it shows symptoms such as bone pain, yellow skin, headache, and balance problems.

Some diagnosis test are performed by doctors to detect the lung cancer including diagnostic imaging test like X-ray, MRI, Ultrasound, CT scan, PET scan, etc. and also by checking the mucous when the patient cough up for cancer cells, which is called as sputum cytology. Moreover, it is also detected by taking the cells of your lungs from abnormal growth area of your lung or from the fluid of lungs which is called as fine needle aspiration biopsy, bronchoscopy and Mediastinoscopy.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/241

Global Non-small cell lung cancer market (NSCLC) taxonomy:

Global NSCLC Market by Type of NSCLC

Adenocarcinoma
Squamous cell carcinoma
Large cell carcinoma
Large cell neuroendocrine tumors

Global NSCLC Market by Type of Treatment

Surgery
Chemotherapy
Targeted therapy
Radiation therapy

Global NSCLC Market by Geography

North America
Europe
APAC
Latin America
Middle East
Africa

Increasing research and development on drugs and the prevalence of lung cancer are major factors driving growth of the global non-small cell lung cancer market

Non-small cell lung cancer is the leading cause of cancer related mortality in the U.S. According to the data of American Cancer Society, Inc. (ACSI), NSCLC is the second-most common type of cancer found in both men and women. According to the same souce, in 2017 there were around 222,500 new cases of lung cancer and 155,870 deaths due to lung cancer in the U.S.

Read Press Release: https://www.coherentmarketinsights.com/press-release/non-small-cell-lung-cancer-treatment-market-2872

Therefore, the North America accounts for the largest market share of the global non-small cell lung cancer market followed by Europe due to large number of smokers present in the region. Furthermore, in the recent past, Asia Pacific has shown increased number of smokers. According to International Association for the Study of Lung Cancer (IASLC), China is the world’s largest consumer of tobacco having around 301 million smokers. According to the data published by World Health Organization (WHO), in 2012, there were around 58% of NSCLC cases occurred in less developed regions.

Growing prevalence and incident rate of lung cancer and emerging drugs coupled with increasing awareness regarding lung cancer treatment is expected to support the global non-small cell lung cancer market growth. However, lack of awareness regarding treatment options in emerging economies, availability of generic drugs, lack of research and development about drugs, and increased expenditure on advertisements of tobacco products are expected to restrain the market growth in the near future. According to the IASLC, in 2012, tobacco industry invested $ 9.6 billion on tobacco products advertising and promotion, which is 40 times higher than NIH research, which spent $ 233 million on lung cancer research.

Furthermore, in October 2016, Merck & Co., Inc. received the U.S. Food and Drug Administration (FDA) approval for pembrolizumab, which is indicated for the treatment of NSCLC.

Key players operating in the global non-small cell lung cancer are AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Agennix AG, ArQule Inc., GlaxoSmithKline Pharmaceuticals Limited, Daiichi Sankyo Co. Ltd., Sanofi-Aventis, and Boehringer Ingelheim GmbH.

Key Developments

Key players in the market are involved in various growth strategies such as gaining product approval from regulatory authorities, in order gain competitive edge in the market. For instance, in August 2019, Roche Holding received the U.S. Food and Drug Administration (FDA) approval for Rozlytrek (entrectinib) for the treatment in adults with ROS1-positive, metastatic non-small cell lung cancer.
Major market players are focused on various business strategies such as research and development, in order to enhance their market position. For instance, in March 2019, Eli Lily and Company announced the positive result for its Phase 3 RELAY study of CYRAMZA (ramucirumab), meeting primary endpoint of progression-free survival (PFS) and exhibited impressive improvement in patients that lived without their cancer spreading or growing after treatment. CYRAMZA is indicated for the treatment of non-small cell lung cancer.
Key players in the market are involved in various business strategies such as collaboration and partnership, in order to develop novel cancer treatments and gain competitive edge in the global market. For instance, in February 2019, GlaxoSmithKline Pharmaceuticals Limited (GSK) and Merck KGaA, Darmstadt, Germany collaborated to jointly develop and commercialize M7824, which is a novel immunotherapy for difficult-to-treat cancers. This novel immunotherapy is also indicated for non-small cell lung cancer.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/market-insight/non-small-cell-lung-cancer-market-241

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Overview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snippet, By Type
  - Market Snippet, By Treatment
  - Market Snippet, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Impact Analysis
- Drug Approvals and Launches
- Market Trends
- Epidemiology
- Diagnosis Information & Treatment Choices
- Genomic Testing
- Packaging Information
- Supply Chain Analysis
- Cancer Initiatives
- Pipeline Analysis
- Regulatory Scenario
- Reimbursement Scenario
Global Non-small Cell Lung Cancer Treatment Market, By Type, 2019 – 2027, (US$ Million)
- Introduction
  - Market Share Analysis, 2019 and 2027 (%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Segment Trends
- Adenocarcinoma
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Large Cell Neuroendocrine Tumors
Global Non-small Cell Lung Cancer Treatment Market, By Treatment, 2019 – 2027, (US$ Million)
- Introduction
  - Market Share Analysis, 2019 and 2027 (%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Segment Trends
- Chemotherapy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Targeted Therapy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    - Bevacizumab (Avastin)
    - Necitumumab (Portrazza)
    - Ramucirumab (Cyramza)
- Immunotherapy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    - Nivolumab (Opdivo)
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    - Atezolizumab (Tecentriq)
    - Others
Global Non-small Cell Lung Cancer Treatment Market, By Region, 2019 – 2027 (US$ Million)
- Introduction
  - Market Share Analysis, 2019 and 2027 (%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Regional Trends
- North America
  - Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Treatment , 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
    - U.S.
    - Canada
- Europe
  - Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Treatment , 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
    - U.K.
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Treatment , 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
    - China
    - Japan
    - India
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Latin America
  - Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Treatment , 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Africa
  - Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Treatment , 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
    - North Africa
    - Central Africa
    - South Africa
- Middle East
  - Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Treatment , 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
    - GCC Countries
    - Israel
    - Rest of Middle East
Competitive Landscape
- Company Profiles
  - Pfizer Inc.*
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - AstraZeneca plc
  - F. Hoffmann-La Roche Ltd.
  - Eli Lilly and Company
  - Boehringer Ingelheim GMBH
  - Novartis AG
  - Bristol-Myers Squibb Company
  - Merck & Co., Inc.
Section
- References
- Research Methodology
- About Us and Sales Contact

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

Company:
- CDN Newswire

Last Updated: 02-Mar-2021